拨康视云™
Cloudbreak Pharma

CLOUDBREAK PHARMA INC.
撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

VOLUNTARY ANNOUNCEMENT

VOLUNTARY EXTENSION OF LOCK-UP PERIOD GIVEN BY A CORNERSTONE INVESTOR

This announcement is made by Cloudbreak Pharma Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform its shareholders and potential investors of an extension of lock-up period given by one of the Cornerstone Investors in respect of its shares (the "**Shares**") in the Company.

References are made to: (a) the prospectus of the Company dated 24 June 2025 (the "**Prospectus**"); and (b) the announcement of the results of allotment of the Company dated 2 July 2025 (the "**Allotment Results Announcement**"). Unless otherwise defined herein, capitalised terms have the meanings given to them in the Prospectus.

As disclosed in the Prospectus and the Allotment Results Announcement, pursuant to the Cornerstone Investment Agreements, each of the Cornerstone Investors has agreed that, without the prior written consent of each of our Company, the Joint Sponsors, the Overall Coordinators and the Joint Global Coordinators, it will not, and will cause its affiliates not to, whether directly or indirectly, at any time during the period commencing from (and inclusive of) the Listing Date and ending on (and inclusive of) the date falling six months after the Listing Date (the "**Original Lock-up Period**"), directly or indirectly (i) dispose of, in any way, any of the Offer Shares it has subscribed for pursuant to the relevant Cornerstone Investment Agreement, including any securities convertible into or exchangeable or exercisable for or that represent the right to receive any of the forgoing securities; (ii) agree, enter into an agreement or publicly announce an intention to enter into such transaction described in (i); (iii) allow itself to undergo a change of control (as defined in the Takeovers Code) at the level of its ultimate beneficial owner; or (iv) enter into any transactions directly or indirectly with the same economic effect as any aforesaid transaction, save for certain limited circumstances, such as transfers to any of its wholly-owned subsidiaries which will be bound by the same obligations of such Cornerstone Investor, including the Original Lock-up Period restriction. In the event of a disposal of any Offer Shares it has subscribed for pursuant to the relevant Cornerstone Investment Agreement at any time after the Original Lock-up Period, the relevant Cornerstone Investor shall notify our Company, the Overall Coordinators and the Joint Sponsors in writing prior to the proposed disposal and shall ensure that (a) such disposal will comply with all applicable laws; and (b) the relevant Cornerstone Investor will use its best endeavours to ensure that the disposal will not create a disorderly and false market in the Shares (the "**Lock-up Undertakings**"). The last day of the Original Lock-up Period falls on 2 January 2026.

The board of directors of the Company (the "**Board**") is pleased to announce that, on 1 January 2026, the Company received a letter of voluntary undertaking (the "**Voluntary Undertaking**") given by Wealth Strategy Holding Limited ("**WSH**"), being one of the Cornerstone Investors, pursuant to which WSH has voluntarily undertaken to the Company to extend the Lock-up Undertakings in respect of the Offer Shares it has subscribed for pursuant to the relevant Cornerstone Investment Agreement, including any securities convertible into or exchangeable or exercisable for or that represent the right to receive any of the forgoing securities, for a further period commencing from and including the date immediately following the expiration of the Original Lock-up Period (namely, 3 January 2026) up to and until the expiration of six (6) months from the said date (namely, 2 July 2026), or such earlier date as may be mutually agreed by the Company and WSH. The Voluntary Undertaking was given by WSH in favour of the Company only and does not create any obligation of WSH towards the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators or any other person.

As at the date of this announcement, WSH holds a total of 15,544,000 Shares, representing approximately 1.84% of the total number of Shares in issue.

The Board believes that the abovementioned voluntary extension of lock-up period by WSH indicates WSH's confidence in the Company's future prospects and recognition of positive developments in the Group's business, including but not limited to significant advances made in the clinical development and commercialisation of the Group's drug candidates, as disclosed in the interim report for the period of six (6) months ended 30 June 2025 published by the Company on 25 September 2025 and the business update announcements published on a voluntary basis by the Company dated 27 November 2025, 8 December 2025, 12 December 2025 and 15 December 2025, respectively.

Shareholders and potential investors of the Company should exercise caution and due care when dealing in the securities of the Company.

By order of the Board
Cloudbreak Pharma Inc.
Dr. NI Jinsong
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 2 January 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van and Dr. Yang Rong as executive directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive directors; and (iii) Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter and Mr. Lee Alex Jao Jang as independent non-executive directors.

* *For identification purpose only*